Multicenter,Randomized,Double-Blind Study Comparing 20 and 40 mg of Pantoprazole for Symptom Relief in Adolescents (12 to 16 Years of Age) with Gastroesophageal Reflux Disease (GERD)
Restricted accessResearch articleFirst published online October, 2006
Multicenter,Randomized,Double-Blind Study Comparing 20 and 40 mg of Pantoprazole for Symptom Relief in Adolescents (12 to 16 Years of Age) with Gastroesophageal Reflux Disease (GERD)
An age-appropriate questionnaire (GASP-Q) was used to assess the frequency and severity of the gastroesophageal reflux disease (GERD) symptoms: abdominal/belly pain, chest pain/heartburn, pain after eating, nausea, burping/belching, vomiting/regurgitation, choking when eating, and difficulty swallowing, in adolescents age 12 to 16 years. The primary objective was to compare the mean composite symptom score (CSS) at week 8 with baseline after treatment with 20 or 40 mg of pantoprazole. Statistically significant (p < 0.001) improvement in CSS occurred in both groups. Safety was comparable between the 2 groups. Pantoprazole was safe, well tolerated, and effective in reducing symptoms of GERD in adolescents.
Get full access to this article
View all access options for this article.
References
1.
Rudolph CD, Mazur LJ, Liptak GS, et al.Guidelines for Evaluation of Gastroesophageal Reflux in Infants and Children: Recommendations of the North American Society for Pediatric Gastroenterology and Nutrition. J Pediatr Gastroenterol Nutr.2001; 32(Suppl 2): S1-S31.
2.
Gold BD.Gastroesophageal reflux disease: could intervention in childhood reduce the risk of later complications?Am J Med. 2004; 117: 23s-29s.
3.
Cuthrell C, Rubino C, Ransom JL, et al.GERD in neonates and pediatrics: use of omeprazole. Pharm Pract.1999; 12: 492-503.
Waring JP, Feiler MJ, Hunter JG, et al.Childhood gasroesophageal reflux symptoms in adult patients. J Pediatr Gastroenterol Nutr.2002; 35: 334-338.
6.
Gunasekaran TS, Hassel E.Efficacy and safety of omeprazole for severe gastroesophageal reflux in children. J Pediatr.1993; 123: 148-154.
7.
Hassall E, Israel D, Shepherd RW, et al.Omeprazole for treatment of chronic erosive esophagitis in children: a multicenter study of efficacy, safety, tolerability and dose requirements. J Pediatr. 2000; 137: 800-807.
8.
Andersson T, Hassall E, Lundborg P, et al.Pharmacokinetics of orally administered omeprazole in children. Am J Gastroenterol.2000; 95: 3101-3106.
9.
Faure C, Michaud L, Shaghaghi E, et al.Intravenous omeprazole in children: pharmacokinetics and effect on 24-hour intragastric pH. J Pediatr Gastroenterol Nutr.2001; 33: 144-148.
10.
Israel D, Hassall E.Omeprazole and other proton pump inhibitors: pharmacology, efficacy, and safety, with special reference to use in children. J Pediatr Gastroenterol Nutr. 1998; 27: 568-579.
11.
Kearns GL, Andersson T, James LP, et al.Omeprazole disposition in children following single-dose administration. J Clin Pharmacol.2003; 43: 840-848.
12.
Zimmerman AE, Walters JK, Katona BG, et al.A review of omeprazole use in the treatment of acid-related disorders in children. Clin Ther. 2001; 23: 660-679.
13.
Tolia V, Fitzgerald J, Hassall E, et al.Safety of lansoprazole in the treatment of GERD in children. J Pediatr Gastroenterol Nutr. 2002; 35: S300-S307.
14.
James LP, Kearns GL.Pharmacokinetics-pharmacodynamic study of oral lansoprazole in children. Clin Pharmacol Ther. 1996; 31: 103-110.
15.
Faure C, Michaud L, Shaghaghi E, et al.Lanzoprazole in children: pharmacokinetics and effecacy in reflux esophagitis. Aliment Pharmacol Ther. 2001; 15: 1397-1402.
16.
Franco MT, Salvia G, Terrin G, et al.Lansoprazole in the treatment of gastro-oesophageal reflux disease in childhood. Dig Liv Dis.2000; 32: 860-866.
17.
Meyer UA.Metabolic interactions of the proton-pump inhibitors lansoprazole, omeprazole and pantoprazole with other drugs. Eur J Gastroenterol Hepatol.1996; 8: S21-S25.
18.
Steinijans VW, Huber R, Hartmann M, et al.Lack of pantoprazole drug interactions in man: an updated review. Int J Clin Pharmacol Ther. 1996; 34: S31-S50.
19.
Tucker GT.The interaction of proton pump inhibitors with cytochromes P450. Aliment Pharmacol Ther.1994; 8: 33-38.
20.
Huber R, Kohl B, Sachs G, et al.Review article: the continuing development of proton pump inhibitors with particular reference to pantoprazole. Aliment Pharmacol Ther. 1995; 9: 363-378.
21.
Kearns GL, Ferron G, James LP, et al.Pantoprazole disposition in pediatrics (abstract). Clin Pharmacol Ther. 2003; 72(Suppl 2): p42-p42.
22.
Madrazo-de la Garza A, Dibildox M, Vargas A, et al.Efficacy and safety of oral pantoprazole 20 mg given once daily for reflux esophagitis in children. J Pediatr Gastroenterol Nutr.2003; 36: 261-265.
23.
McVeigh K, Wetzel R.Issues in pediatric critical care medicine. Semin Anesth.1999; 18: 204-215.
24.
Williams CN.Gastroesophageal reflux disease. Can J Gastroenterol. 1998; 12: 107-108.
25.
Treem WR, Davis PM, Hyams JS.Gastroesophageal reflux in the older child: presentation, response to treatment and long-term follow-up. Clin Pediatr.1991; 30: 435-440.
26.
Kreh R, Czinn S, Cheliminsky G, et al.A symptom scoring instrument for reproducibly determining helicobacter pylori-associated gastrointestinal symptoms in children. J Pediatr Gastroenterol Nutr.2001; 33: 388-392.
27.
Ferron G, James LP, Kearns GL, et al.Pharmacokinetics of oral pantoprazole in pediatric patients. Pharmacotherapy.2002; 22: 1358-1358.
28.
Dammann HG.Pantoprazole in pediatric patients with peptic ulcer and reflex esophagitis. Med Klin. 1998; Welt(3): 7-9.
